Dynavax Reaffirms 2024 HEPLISAV-B Net Product Revenue Guidance Of $265M-$280M
Portfolio Pulse from Benzinga Newsdesk
Dynavax Technologies has reaffirmed its 2024 net product revenue guidance for HEPLISAV-B, projecting revenues between $265 million and $280 million.
August 06, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dynavax Technologies has reaffirmed its 2024 net product revenue guidance for HEPLISAV-B, projecting revenues between $265 million and $280 million.
Reaffirming revenue guidance is a positive signal to investors, indicating confidence in the company's product performance and financial outlook. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100